RhumbLine Advisers
MPLT

RhumbLine Advisers’s MapLight Therapeutics MPLT Stock Holding History

RhumbLine Advisers’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$564K Sell
15,748
-4,620
-23% -$133K ﹤0.01% 2685
2026
Q1 		$414K Buy
20,368
+6,726
+49% +$120K ﹤0.01% 2724
2025
Q4 		$240K Buy
+13,642
New +$229K ﹤0.01% 3091

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RhumbLine Advisers's MPLT Position: Q2 2026 in Review

RhumbLine Advisers reduced its MapLight Therapeutics (MPLT) stake by 23% in Q2 2026, selling an estimated $133K and leaving 15,748 shares worth $564K. The position accounts for ﹤0.01% of the portfolio, ranked #2685.

RhumbLine Advisers first reported a position in MPLT in Q4 2025 and has held it in 3 quarters since. 100 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • RhumbLine Advisers held 15,748 shares of MapLight Therapeutics worth $564K as of Q2 2026.
  • RhumbLine Advisers sold 4,620 MapLight Therapeutics shares in Q2 2026, an estimated $133K.
  • MapLight Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2685 holding.
  • RhumbLine Advisers first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 100 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.